{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T02:44:22Z","timestamp":1785725062334,"version":"3.56.0"},"reference-count":81,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T00:00:00Z","timestamp":1785628800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001459","name":"Ministry of Education","doi-asserted-by":"publisher","award":["RS-2025-25441317"],"award-info":[{"award-number":["RS-2025-25441317"]}],"id":[{"id":"10.13039\/501100001459","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: Small-cell lung cancer (SCLC) remains one of the most therapeutically challenging malignancies despite recent advances in chemoimmunotherapy. Although platinum\u2013etoposide combined with programmed death ligand 1 (PD-L1) blockade has modestly improved survival in extensive-stage disease, most patients ultimately develop treatment resistance. This review examines the evolving biological basis of therapeutic resistance and discusses how emerging treatment strategies may be integrated into biologically informed clinical development. Methods: We conducted a narrative review of recent translational studies, clinical trials, regulatory updates, and major oncology meeting presentations addressing emerging therapeutic strategies, biomarkers, and adaptive resistance mechanisms in SCLC. Results: Advances in molecular profiling have established that SCLC comprises dynamically evolving transcriptional states characterized by lineage plasticity, replication-stress dependency, immune suppression, and antigen remodeling. These biological insights have accelerated the development of delta-like ligand 3 (DLL3)-directed immune-redirection strategies, next-generation antibody\u2013drug conjugates, DNA damage response-targeting therapies, and epigenetic approaches. Across these platforms, however, clinical translation remains constrained by antigen heterogeneity, biomarker instability, lineage plasticity, immune dysfunction, and cumulative toxicity. We organize the available evidence across three clinically relevant treatment windows\u2014induction, post-induction residual disease, and relapse\u2014to clarify how therapeutic timing may influence the role and expected clinical performance of each strategy. Conclusions: Future clinical development should prioritize the prospective validation of dynamic biomarkers and treatment strategies tailored to specific disease stages. Such an approach may improve patient selection, guide therapeutic sequencing, and increase the durability of treatment benefit in extensive-stage SCLC.<\/jats:p>","DOI":"10.3390\/ph19081217","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T01:43:27Z","timestamp":1785721407000},"page":"1217","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emerging Therapeutic Strategies in Small-Cell Lung Cancer: From Adaptive Resistance to Precision Therapy"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9115-8278","authenticated-orcid":false,"given":"Jun","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Chemistry, Soongsil University, Seoul 06978, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seounghun","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Soongsil University, Seoul 06978, Republic of Korea"},{"name":"AI-Bio Convergence Research Institute, Soongsil University, Seoul 06978, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrclinonc.2017.71","article-title":"Unravelling the biology of SCLC: Implications for therapy","volume":"14","author":"Sabari","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Dvorkin","year":"2019","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum\u2013etoposide versus platinum\u2013etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): Updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","article-title":"Molecular subtypes of small cell lung cancer: A synthesis of human and mouse model data","volume":"19","author":"Rudin","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","article-title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","volume":"39","author":"Gay","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"302ra136","DOI":"10.1126\/scitranslmed.aac9459","article-title":"A DLL3-targeted antibody\u2013drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo","volume":"7","author":"Saunders","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.jtho.2021.02.009","article-title":"Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: Results from the phase 3 TAHOE study","volume":"16","author":"Blackhall","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Muscolino, P., Omero, F., Speranza, D., Infurna, C., Parisi, S., Cianci, V., Berretta, M., Russo, A., and Santarpia, M. (2025). ADCs and TCE in SCLC therapy: The beginning of a new era?. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32050261"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1158\/2159-8290.CD-20-0913","article-title":"Intrinsic immunogenicity of small cell lung carcinoma revealed by its cellular plasticity","volume":"11","author":"Mahadevan","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/cncr.29098","article-title":"Small cell lung cancer: Where do we go from here?","volume":"121","author":"Byers","year":"2015","journal-title":"Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1158\/2159-8290.CD-12-0112","article-title":"Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1","volume":"2","author":"Byers","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1200\/JCO.2018.77.7672","article-title":"Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer","volume":"36","author":"Pietanza","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41416-024-02745-0","article-title":"ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors","volume":"131","author":"Smith","year":"2024","journal-title":"Br. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ccell.2016.12.005","article-title":"MYC drives progression of small cell lung cancer to a variant neuroendocrine subtype with vulnerability to aurora kinase inhibition","volume":"31","author":"Mollaoglu","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ccell.2020.05.001","article-title":"MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate","volume":"38","author":"Ireland","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ccell.2017.01.006","article-title":"Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 axis","volume":"31","author":"Gardner","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"28575","DOI":"10.18632\/oncotarget.15338","article-title":"Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer","volume":"8","author":"Stewart","year":"2017","journal-title":"Oncotarget"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","article-title":"Rovalpituzumab tesirine, a DLL3-targeted antibody\u2013drug conjugate, in recurrent small-cell lung cancer: A first-in-human, first-in-class, open-label, phase 1 study","volume":"18","author":"Rudin","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"mdy374.027","DOI":"10.1093\/annonc\/mdy374.027","article-title":"Phase 1 study on safety and pharmacokinetics of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small-cell lung cancer","volume":"29","author":"Tanaka","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.jtho.2024.09.057","article-title":"Tarlatamab sustained clinical benefit and safety in previously treated SCLC: DeLLphi-301 phase 2 extended follow-up","volume":"19","author":"Sands","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"TPS8136","DOI":"10.1200\/JCO.2026.44.16_suppl.TPS8136","article-title":"A randomized, open-label, phase 3 study of ZL-1310, a DLL3 antibody\u2013drug conjugate, compared with investigator\u2019s choice therapy in participants with relapsed small-cell lung cancer (DLLEVATE)","volume":"44","author":"Dowlati","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e524964","DOI":"10.1200\/EDBK-26-524964","article-title":"Updates in small cell lung cancer treatment: No longer too small to ignore\u2014A review of recent therapeutic advances","volume":"46","author":"Arya","year":"2026","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/jcph.2346","article-title":"Clinical pharmacology profile of AMG 119, the first chimeric antigen receptor T-cell therapy targeting delta-like ligand 3, in patients with relapsed\/refractory small-cell lung cancer","volume":"64","author":"Zhou","year":"2024","journal-title":"J. Clin. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12943-024-02012-z","article-title":"DLL3-guided therapies in small-cell lung cancer: From antibody\u2013drug conjugate to precision immunotherapy and radioimmunotherapy","volume":"23","author":"Su","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Wang, H., Zheng, T., Xu, D., Sun, C., Huang, D., and Liu, X. (2025). Targeting DLL3: Innovative strategies for tumor treatment. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17040520"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-15-2428","article-title":"Molecular pathways: Targeting B7-H3 (CD276) for human cancer immunotherapy","volume":"22","author":"Picarda","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"108723","DOI":"10.1016\/j.lungcan.2025.108723","article-title":"Impact of B7-H3 and DLL3 expression on the efficacy of PD-L1 blockade therapy in extensive-stage small-cell lung cancer","volume":"202","author":"Kurosaki","year":"2025","journal-title":"Lung Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1200\/JCO-25-02142","article-title":"Ifinatamab deruxtecan in patients with extensive-stage small-cell lung cancer: Primary analysis of the phase II IDeate-Lung01 trial","volume":"44","author":"Rudin","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ccell.2026.02.006","article-title":"HS-20093, a B7-H3-targeted antibody\u2013drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a\/b trial","volume":"44","author":"Duan","year":"2026","journal-title":"Cancer Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jtho.2024.12.028","article-title":"Phase 2 open-label study of sacituzumab govitecan as second-line therapy in patients with extensive-stage SCLC: Results from TROPiCS-03","volume":"20","author":"Dowlati","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1158\/1535-7163.MCT-21-0851","article-title":"ABBV-011, a novel calicheamicin-based antibody\u2013drug conjugate, targets SEZ6 to eradicate small-cell lung cancer tumors","volume":"21","author":"Wiedemeyer","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1200\/JCO.2024.42.16_suppl.3001","article-title":"First-in-human study of ABBV-706, a seizure-related homolog protein 6-targeting antibody\u2013drug conjugate, in patients with advanced solid tumors","volume":"42","author":"Chandana","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.trecan.2024.07.008","article-title":"Small cell lung cancer profiling: An updated synthesis of subtypes, vulnerabilities, and plasticity","volume":"10","author":"Redin","year":"2024","journal-title":"Trends Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.2217\/fon-2022-0196","article-title":"Phase I trial of the DLL3\/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas","volume":"18","author":"Wermke","year":"2022","journal-title":"Future Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1158\/1535-7163.MCT-23-0524","article-title":"HPN328, a trispecific T-cell\u2013activating protein construct targeting DLL3-expressing solid tumors","volume":"23","author":"Molloy","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1200\/JCO.2026.44.16_suppl.4004","article-title":"A randomized phase II dose-optimization study for alveltamig (ZG006), a trispecific T-cell engager targeting DLL3\/DLL3\/CD3, as monotherapy in patients with refractory neuroendocrine carcinoma (ZG006-003)","volume":"44","author":"Zhao","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1158\/1538-7445.AM2022-2908","article-title":"PT217, an anti-DLL3\/anti-CD47 bispecific antibody, exhibits antitumor activity through novel mechanisms of action","volume":"82","author":"Jia","year":"2022","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1158\/0008-5472.CAN-17-2176","article-title":"Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer","volume":"78","author":"Meder","year":"2018","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"103854","DOI":"10.1016\/j.jtho.2026.103854","article-title":"PP01.120: Global phase 2 randomized trial of pumitamig (BNT327\/BMS986545; PD-L1 \u00d7 VEGF-A bsAb) plus chemotherapy for 1L ES-SCLC: Dose optimization analysis","volume":"21","author":"Heymach","year":"2026","journal-title":"J. Thorac. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Venugopala, K.N. (2022). Targeting the DNA damage response machinery for lung cancer treatment. Pharmaceuticals, 15.","DOI":"10.3390\/ph15121475"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Bian, X., and Lin, W. (2019). Targeting DNA replication stress and DNA double-strand break repair for optimizing SCLC treatment. Cancers, 11.","DOI":"10.3390\/cancers11091289"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.18.00264","article-title":"Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 study","volume":"37","author":"Owonikoko","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1158\/1078-0432.CCR-16-1040","article-title":"PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer","volume":"23","author":"Lok","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"S329","DOI":"10.21037\/tlcr.2018.12.02","article-title":"Temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer","volume":"7","author":"Lazzari","year":"2018","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/s41416-021-01476-w","article-title":"A wake-up call for cancer DNA damage: The role of Schlafen 11 (SLFN11) across multiple cancers","volume":"125","author":"Zhang","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/1538-7445.AM2026-248","article-title":"Nesuparib (JPI-547), a dual tankyrase\/PARP inhibitor, exhibits potent antitumor activity in small-cell lung cancer models by modulating Wnt and Hippo signaling pathways","volume":"86","author":"Kim","year":"2026","journal-title":"Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1158\/1538-7445.AM2018-2822","article-title":"ATR inhibitors are active as single agents and in combination with PARP1 and ATM inhibitors in molecularly distinct subsets of small cell lung cancer models","volume":"78","author":"Gay","year":"2018","journal-title":"Cancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1158\/1078-0432.CCR-17-1284","article-title":"Targeting AXL and mTOR pathway overcomes primary and acquired resistance to WEE1 inhibition in small-cell lung cancer","volume":"23","author":"Sen","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1158\/1078-0432.CCR-17-2805","article-title":"The combination of the PARP inhibitor olaparib and the WEE1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer","volume":"24","author":"Lallo","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Rundle, S., Bradbury, A., Drew, Y., and Curtin, N.J. (2017). Targeting the ATR\u2013CHK1 axis in cancer therapy. Cancers, 9.","DOI":"10.3390\/cancers9050041"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/cncr.35059","article-title":"Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer","volume":"130","author":"Park","year":"2024","journal-title":"Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00280-019-03950-y","article-title":"Prexasertib, a checkpoint kinase inhibitor: From preclinical data to clinical development","volume":"85","author":"Angius","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s11523-024-01102-8","article-title":"Adavosertib in combination with olaparib in patients with refractory solid tumors: An open-label, dose-finding, and dose-expansion phase Ib trial","volume":"19","author":"Hamilton","year":"2024","journal-title":"Target. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","article-title":"Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer","volume":"9","author":"Sen","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"eaau2922","DOI":"10.1126\/scisignal.aau2922","article-title":"Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition","volume":"12","author":"Augert","year":"2019","journal-title":"Sci. Signal."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ccell.2015.06.002","article-title":"A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC","volume":"28","author":"Mohammad","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Coe, B.P., Thu, K.L., Aviel-Ronen, S., Vucic, E.A., Gazdar, A.F., Lam, S., Tsao, M.-S., and Lam, W.L. (2013). Genomic deregulation of the E2F\/Rb pathway leads to activation of the oncogene EZH2 in small cell lung cancer. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0071670"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/JTO.0b013e318298762f","article-title":"EZH2 promotes E2F-driven SCLC tumorigenesis through modulation of apoptosis and cell-cycle regulation","volume":"8","author":"Hubaux","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/318069a0","article-title":"L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer","volume":"318","author":"Nau","year":"1985","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1038\/s41388-025-03481-2","article-title":"Integrative epigenome and transcriptome analyses reveal transcriptional programs differentially regulated by ASCL1 and NEUROD1 in small cell lung cancer","volume":"44","author":"Takumida","year":"2025","journal-title":"Oncogene"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jtho.2020.09.009","article-title":"SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: A comprehensive immunohistochemical and histopathologic characterization","volume":"15","author":"Baine","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Galetta, D., and Cortes-Dericks, L. (2020). Promising therapy in lung cancer: Spotlight on aurora kinases. Cancers, 12.","DOI":"10.3390\/cancers12113371"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"eabc2578","DOI":"10.1126\/sciadv.abc2578","article-title":"Prototypical oncogene family Myc defines unappreciated distinct lineage states of small cell lung cancer","volume":"7","author":"Patel","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1158\/1535-7163.MCT-15-0037","article-title":"Sensitivity of small cell lung cancer to BET inhibition is mediated by regulation of ASCL1 gene expression","volume":"14","author":"Lenhart","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"106756","DOI":"10.1016\/j.esmoop.2026.106756","article-title":"442TiP DeLLphi-312 phase III trial-in-progress: Tarlatamab with durvalumab, carboplatin and etoposide versus durvalumab, carboplatin and etoposide as first-line therapy in extensive-stage small cell lung cancer","volume":"11","author":"Korantzis","year":"2026","journal-title":"ESMO Open"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"107924","DOI":"10.1016\/j.lungcan.2024.107924","article-title":"Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the phase III IMpower133 study and the phase III IMbrella A extension study","volume":"196","author":"Reck","year":"2024","journal-title":"Lung Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0140-6736(25)01011-6","article-title":"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): A randomised, multicentre, open-label, phase 3 trial","volume":"405","author":"Borghaei","year":"2025","journal-title":"Lancet"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S1470-2045(25)00480-2","article-title":"Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): A multicentre, non-randomised, phase 1b study","volume":"26","author":"Paulson","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_73","first-page":"S206","article-title":"P1.13A.02 Tarlatamab plus durvalumab as first-line maintenance in extensive-stage small cell lung cancer: DeLLphi-305 phase 3 trial","volume":"19","author":"Ahn","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jtho.2017.09.1951","article-title":"Longitudinal cell-free DNA analysis in patients with small cell lung cancer reveals dynamic insights into treatment efficacy and disease relapse","volume":"13","author":"Almodovar","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jtho.2019.10.007","article-title":"Profiling of circulating free DNA using targeted and genome-wide sequencing in patients with SCLC","volume":"15","author":"Mohan","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1080\/14796694.2025.2565995","article-title":"IDeate-Lung02: A phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer","volume":"21","author":"Owonikoko","year":"2025","journal-title":"Future Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1158\/1538-7445.AM2024-3148","article-title":"Abstract 3148: ABBV-706 is a novel SEZ6-targeted topoisomerase 1 inhibitor ADC for SCLC and other neuroendocrine cancers","volume":"84","author":"Faivre","year":"2024","journal-title":"Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1158\/1535-7163.MCT-16-0172","article-title":"Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation of DNA breaks in cancer cells","volume":"15","author":"Giraudon","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: A single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.21037\/tlcr-2025-216","article-title":"Sacituzumab govitecan: A new hope for patients with pretreated extensive small-cell lung cancer\u2014Insights from the TROPiCS-03 trial","volume":"14","author":"Abbar","year":"2025","journal-title":"Transl. Lung Cancer Res."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/8\/1217\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T01:47:39Z","timestamp":1785721659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/8\/1217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,2]]},"references-count":81,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["ph19081217"],"URL":"https:\/\/doi.org\/10.3390\/ph19081217","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,2]]}}}